Yaso is an early stage drug development company developing a line of prophylactic products for women and men designed to prevent sexually transmitted disease and unintended pregnancy. With a proven track record of success in women's reproductive health products, the firms has the worldwide license for a unique polymeric drug with which the firm is currently developing several dosage forms for preclinical evaluation. Yaso is dedicated to the discovery and development of products to prevent the spread of sexually transmitted infections and sexually transmitted HIV. The firm's current research is in the field of microbicides. The firm has the worldwide license to a drug, PPCM, that promises to prevent infections during sexual intercourse. PPCM, is the only drug under development that promises to be both contraceptive and prevent viral and bacterial STIs.
